The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 07, 2025

Filed:

Aug. 22, 2023
Applicants:

Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;

Agency for Science, Technology and Research, Singapore, SG;

Inventors:

Zenjiro Sampei, Shizuoka, JP;

Xing'er Christine Koo, Singapore, SG;

Katja Fink, Singapore, SG;

Roland Zuest, Singapore, SG;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/10 (2006.01); A61K 39/12 (2006.01); A61K 39/395 (2006.01); A61P 31/12 (2006.01); C07K 14/005 (2006.01); C07K 16/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/1081 (2013.01); A61P 31/12 (2018.01); A61K 2039/505 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); Y02A 50/30 (2018.01);
Abstract

The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding the anti-DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in a parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1 q-binding activity when compared to the parent Fc region.


Find Patent Forward Citations

Loading…